<?xml version="1.0" encoding="UTF-8"?>
<p id="Par29">For product testing and release, platform analytics for IgG1 mAbs enable rapid cGMP product release. Release specifications could be established using typical ranges for mAbs in phase 1 studies without the need for product-specific limits unless warranted
 <sup>
  <xref ref-type="bibr" rid="CR20">20</xref>
 </sup>. A more time-consuming test to develop, such as the antigen-binding enzyme-linked immunosorbent assay (ELISA), may be qualified during IND review or performed as ‘confirmatory’ after the IND is filed.
</p>
